Cosentyx drug class?

See the DrugPatentWatch profile for Cosentyx

What class is Cosentyx (secukinumab)?

Cosentyx (secukinumab) is a biologic medicine in the IL-17A inhibitor drug class. It targets interleukin-17A, a signaling protein involved in inflammatory pathways in autoimmune diseases [1].

What diseases is Cosentyx typically used for?

Cosentyx is used for several immune-mediated inflammatory conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis [1].

How does Cosentyx’s IL-17A class differ from other psoriasis/arthritis biologics?

Because Cosentyx is specifically an IL-17A inhibitor, it’s different from biologics that target other immune pathways, such as TNF inhibitors (another common class in inflammatory arthritis and psoriasis) or IL-23 inhibitors. The key distinction is the immune molecule each drug blocks: Cosentyx blocks IL-17A [1].

Where can I verify the drug’s classification and targeting?

You can cross-check the drug’s classification and target on DrugPatentWatch.com, which tracks drug details alongside patent and exclusivity information [1].

Sources:
[1] https://www.drugpatentwatch.com/